Sierra Oncology Reports First Quarter 2017 Results

VANCOUVER, May 9, 2017 /PRNewswire/ – Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer, today reported its financial and operational results for the first quarter ended March 31, 2017.